Also known as

p53-HDM-2 targeting peptide · PNC27 · Anticancer research peptide

Overview

PNC-27 is a p53-derived peptide studied for selective membrane effects on HDM-2–expressing tumor cells in oncology research models. Despite appearing in a cosmetic/topical catalog grouping in v4, it is not a cosmetic ingredient.

Research framing is cancer-cell membrane disruption and apoptosis markers in vitro—not consumer skincare. Left Turn Adventures supplies this compound for laboratory and research use only.

Proven benefits

Note: Preclinical / literature endpoints for labs — not established human treatment benefits. Not a protocol.

• HDM-2–expressing tumor-cell membrane endpoints

• • Selective cytotoxicity markers in oncology models

• • p53-derived peptide apoptosis readouts where studied

• • Membrane-pore / necrosis-adjacent measures in literature

• • Comparative anticancer peptide research framing

Results timeline

Note: Illustrative research-observation windows — not a clinical schedule. No dosing.

• Week 1–2: Early matrix, skin, or antimicrobial readouts in topical/in vitro models.

• • Week 3–4: Clearer collagen, expression-line, or barrier markers in short research windows.

• • Month 2–3: More apparent cosmetic-endpoint changes in extended laboratory designs.

• • Month 3–6: Sustained skin/matrix observations where longer protocols are studied.

Footer RUO

The catalog, not a clinic

For laboratory and research use only. Not for human or animal consumption. Products are sold solely to qualified researchers and licensed laboratories. No dosing or reconstitution on this page.